4 days ago · Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease.

4 days ago · CHICAGO -- (BUSINESS WIRE)--Feb. 3, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics …

3 days ago · Financing was provided by Ares Management Credit funds. Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. About Tempus

4 days ago · Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a ...

Mar 12, 2024 · Utilizing next-generation sequencing, the assays identify genetic variants associated with hereditary cancer syndromes and inherited risk of cancer, and leverages Ambry’s 25-year history of variant interpretation expertise.

Nov 4, 2024 · We will be able to bring Ambry’s 25-year history of leadership in variant interpretation together with Tempus’ multimodal data and robust analytical systems to drive new insights for diagnosing and treating patients.

Nov 4, 2024 · The company also announced that it has entered into an agreement to acquire Ambry Genetics, a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Revenue increased 33.0% year-over-year to $180.9 million in the third quarter of 2024

Mar 12, 2024 · Utilizing next-generation sequencing, the assays identify genetic variants associated with hereditary cancer syndromes and inherited risk of cancer, and leverages Ambry’s 25-year history of...

Nov 6, 2024 · Tempus AI agreed to buy genetic testing company Ambry Genetics for $375 million in cash and $225 million in shares. Chicago-based Tempus, which makes AI-enabled precision medicine solutions, said the purchase will provide expanded testing …

Nov 11, 2024 · Tempus AI has announced its acquisition of Ambry Genetics, from KONICA MINOLTA, INC. for $600 million, comprising $375 million in cash and $225 million in shares. This strategic acquisition expands Tempus’ capabilities in hereditary cancer screening and genetic testing, adding to its precision medicine offerings.